Alumis Inc. · NASDAQ:ALMS
Alumis — Merger or Acquisition (March 2025)
10 slides from Alumis's merger presentation, Mar 18, 2025
Slide 1: Transform Therapies. Reimagine Lives. March 2025 Corporate Presentation
Transform Therapies. Reimagine Lives. March 2025 Corporate Presentation Supplemental Materials
Slide 2: Forward-Looking Statements
2 © Alumis Forward - Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the “safe harb or” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates a nd e
Slide 3: Creating a Leading I&I Company with Multiple Upcoming Milestones and Runway into 2027
1. Preliminary, unaudited and subject to change © Alumis 3 Creating a Leading I&I Company with Multiple Upcoming Expected Development Milestones and Extended Runway into 2027 〉 Creates a late - stage clinical biopharma company dedicated to innovating, developing and commercializing transformative th
Slide 4: Late-Stage Pipeline with Multiple Near-Term Catalysts
Late - Stage Pipeline with Multiple Near - Term Catalysts 4 © Alumis 〉 Post transaction close, we expect to evaluate lonigutamab’s promising potential differentiation profile in TED with approximately $25 - 50M of committed capital and the combined expertise of Alumis and the lonigutamab team ANTICI
Slide 5: Alumis Combination Optimizes Outcome for Patients and ACELYRIN Stockholders
Alumis Combination Optimizes Outcome for Patients and ACELYRIN Stockholders 5 © Alumis Lonigutamab is a Differentiated Molecule for the Treatment of TED and Deserves Continued Exploration for the Benefit of Patients 〉 Potential for commercially attractive product profile with improved safety and IV
Slide 6: Comparing Alternative Options for ACELYRIN Stockholders
© Alumis 6 Comparing Alternative Options for ACELYRIN Stockholders Standalone ACELYRIN Combined Company • Lonigutamab • ESK - 001 • Lonigutamab • A - 005 • IRF5 • Additional Targets Product Candidates • Previously announced start of Phase 3 program in Q1 2025 with topline data in 2H 2026 • Mid - 202
Slide 7: Transaction Has Potential for Substantial Value Creation for ACELYRIN Stockholders
© Alumis 7 We Believe That the Transaction Has Potential for Substantial Value Creation for ACELYRIN Stockholders Notes: 1. In connection with its consideration of the merger, the Board of ACELYRIN considered, among other things, a financial present ati on from Guggenheim Securities, LLC (“Guggenhei
Slide 8: Comprehensive Process Led to Value-Maximizing Opportunity for ACELYRIN Stockholders
8 Comprehensive Process Led to Value - Maximizing Opportunity for ACELYRIN Stockholders © Alumis T he Proposed M erger With Alumis Is the R esult of a Comprehensive P rocess C onducted by ACELYRIN Board 〉 This process began in Q2 2024 and encompassed interactions with ~25 potential counterparties 〉
Slide 9: Alumis + ACELYRIN: A Well Characterized Late-Stage Portfolio With Significant Opportunity
9 Alumis + ACELYRIN: A Well Characterized Late - Stage Portfolio With Significant Opportunity Genomic, proteomic and clinical insights validate and drive our Research and Development strategy and increase the probability of technical success (PTS) of our programs Experienced team with strong track r
Slide 10: Thank You!
Thank You! Forward-Looking Statements This communication contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expe